Jubilant Life Sciences’ material wholly owned subsidiary - Jubilant Pharma, through one of its wholly owned subsidiaries, has received a Supplemental New Drug Application (sNDA) approval from US Food and Drug Administration (USFDA) for Draximage DTPA powder for solution. Specifically, Draximage DTPA is a kit for the preparation of Technetium Tc99m pentetate injection.
Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.